BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 29857784)

  • 1. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():893-903. PubMed ID: 31118599
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
    Moll K; Sun SX; Ellis JJ; Howe A; Amin A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [No Abstract]   [Full Text] [Related]  

  • 6. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
    Kwan SW; Mortell KE; Hippe DS; Brunner MC
    J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare costs and utilization associated with muscle weakness diagnosis codes in patients with chronic obstructive pulmonary disease: a United States claims analysis.
    Trantham L; Sikirica MV; Candrilli SD; Benson VS; Mohan D; Neil D; Joshi AV
    J Med Econ; 2019 Apr; 22(4):319-327. PubMed ID: 30580639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
    Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
    Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
    Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
    J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
    Schwab P; Dhamane AD; Hopson SD; Moretz C; Annavarapu S; Burslem K; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2017; 12():735-744. PubMed ID: 28260880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia.
    Lee TY; Johnson A; Cooke CE; Yared JA; Summers A; Yang K; Liu S; Tang B; Onukwugha E
    J Manag Care Spec Pharm; 2024 May; 30(5):430-440. PubMed ID: 38701030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospital Variation in Spending for Lung Cancer Resection in Medicare Beneficiaries.
    Jean RA; Bongiovanni T; Soulos PR; Chiu AS; Herrin J; Kim N; Xu X; Kim AW; Gross CP
    Ann Thorac Surg; 2019 Dec; 108(6):1710-1716. PubMed ID: 31400321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
    Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
    J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare Utilization and Costs During the Initial Phase of Care Among Elderly Women With Breast Cancer.
    Vyas A; Madhavan SS; Sambamoorthi U; Pan XL; Regier M; Hazard H; Kalidindi S
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1401-1409. PubMed ID: 29118232
    [No Abstract]   [Full Text] [Related]  

  • 20. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
    Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
    J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.